Last $45.91 USD
Change Today +0.44 / 0.97%
Volume 562.8K
NVO On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
New York
Frankfurt
Frankfurt
As of 8:04 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for novo-nordisk a/s-spons adr (NVO)

Year over year, Novo Nordisk A/S has been able to grow revenues from kr78.0B DKK to kr83.6B DKK. Most impressively, the company has been able to reduce the percentage of sales devoted to cost of goods sold from 17.26% to 16.92%. This was a driver that led to a bottom line growth from kr21.4B DKK to kr25.2B DKK.
View Income Statement In U.S. Dollar
Currency in
Millions of Danish Krones
As of:Dec 31
2010
Reclassified
DKK
Dec 31
2011
DKK
Dec 31
2012
DKK
Dec 31
2013
DKK
4 Year
Trend
Revenues60,776.066,346.078,026.083,572.0
TOTAL REVENUES60,776.066,346.078,026.083,572.0
Cost of Goods Sold11,680.012,589.013,465.014,140.0
GROSS PROFIT49,096.053,757.064,561.069,432.0
Selling General & Admin Expenses, Total21,260.022,249.024,856.026,888.0
R&D Expenses9,602.09,628.010,897.011,733.0
Other Operating Expenses-657.0-494.0-666.0-682.0
OTHER OPERATING EXPENSES, TOTAL30,205.031,383.035,087.037,939.0
OPERATING INCOME18,891.022,374.029,474.031,493.0
Interest Expense-500.0-275.0-58.0-55.0
Interest and Investment Income235.0274.0125.071.0
NET INTEREST EXPENSE-265.0-1.067.016.0
Currency Exchange Gains (Loss)-1,984.0-322.0-1,529.01,146.0
Other Non-Operating Income (Expenses)1,667.0-99.0-83.0-96.0
EBT, EXCLUDING UNUSUAL ITEMS18,309.021,952.027,929.032,559.0
Gain (Loss) on Sale of Investments-23.0-27.0-118.0-20.0
EBT, INCLUDING UNUSUAL ITEMS18,286.021,925.027,811.032,539.0
Income Tax Expense3,883.04,828.06,379.07,355.0
Earnings from Continuing Operations14,403.017,097.021,432.025,184.0
NET INCOME14,403.017,097.021,432.025,184.0
NET INCOME TO COMMON INCLUDING EXTRA ITEMS14,403.017,097.021,432.025,184.0
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS14,403.017,097.021,432.025,184.0
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVO:US $45.91 USD +0.44

NVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $53.18 USD -0.90
Amgen Inc $122.84 USD +0.58
AstraZeneca PLC 4,392 GBp -32.50
Biogen Idec Inc $335.45 USD -1.34
Bristol-Myers Squibb Co $49.39 USD -0.07
View Industry Companies
 

Industry Analysis

NVO

Industry Average

Valuation NVO Industry Range
Price/Earnings 25.7x
Price/Sales 7.8x
Price/Book 19.4x
Price/Cash Flow 20.3x
TEV/Sales 6.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.